Ospemifene in vulvovaginal atrophy: Added benefit not proven

August 10, 2016

Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy. The drug has been on the market in Germany since May 2016. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether it has advantages or disadvantages in comparison with the appropriate comparator therapy.

As none of the 3 studies presented by the manufacturer is suited to derive such conclusions, IQWiG concludes that an added benefit of ospemifene over the comparator therapy is not proven.

Oestrogen receptor modulator instead of oestrogen

Due to a decrease in oestrogen levels in menopause, the vaginal mucosa regresses and some women may experience vaginal dryness that can lead to pain or itching. Vaginal oestrogen therapy is not suitable for some affected women, for example, due to intolerable side effects.

Ospemifene is a drug from the class of selective oestrogen receptor modulators; these agents and their main metabolic products bind to oestrogen receptors instead of oestrogen and thus have a similar effect to the hormone.

Studies unsuitable

The Federal Joint Committee (G-BA) specified best supportive care or systemic hormone therapy as appropriate comparator therapies. The manufacturer cited 3 randomized controlled trials; however, they are all unsuitable for drawing conclusions on the added benefit of ospemifene. None of the studies specifically included women who were not candidates for local vaginal oestrogen therapy. With a duration of 12 weeks, 2 of the studies were much too short. In one of the studies, symptom severity was not an explicit inclusion criterion.

In addition, the women in the control arms of the studies were allowed neither to use other non-hormonal treatments (except for a specified lubricant) nor to continue systemic hormone therapy already started. Hence the requirements for the appropriate comparator therapy were not correctly implemented. As no suitable data on the research question are available, an added benefit of ospemifene over the appropriate comparator therapy is not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the Federal Joint Committee (G-BA). After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
-end-
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.

Institute for Quality and Efficiency in Health Care

Related Comparator Therapy Articles from Brightsurf:

Combination therapy against cancer
In their quest to destroy cancer cells, researchers are turning to combinational therapies more and more.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Dual therapy reduces risk for bleeding better than triple therapy for patients with atrial fibrillation
Use of dual therapy with a direct oral anticoagulant (DOAC) plus P2Y12 inhibitor was associated with reduced risk for major bleeding compared with triple therapy with a vitamin K antagonist (VKA) plus aspirin and P2Y12 inhibitor for patients with nonvalvular atrial fibrillation after percutaneous coronary intervention (PCI).

Light therapy for immune cells helps with side effects of cancer therapy
A frequent side effect of cancer immunotherapies can probably be stopped by light activation of immune cells, as researchers at the Medical Center -- University of Freiburg have shown.

A new old therapy
The fight against drug-resistant pathogens remains an intense one. While the Centers for Disease Control's (CDC) 2019 'biggest threats' report reveals an overall decrease in drug-resistant microbe-related deaths as compared to its previous report (2013) the agency also cautions that new forms of drug-resistant pathogens are still emerging.

Financial therapy can aid well-being, stability
Financial therapy could help couples navigate disagreements, money concerns and financial conflicts before these issues tear relationships apart.

Diabetes: A next-generation therapy soon available?
Insulin is normally produced by pancreatic β cells. In many people with diabetes, pancreatic cells are not functional, causing a chronic and potentially fatal insulin deficiency that can only be controlled through daily insulin injections.

Hormone therapy associated with improved cognition
Estrogen has a significant role in overall brain health and cognitive function.

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Are we using biologic therapy properly?
The introduction of infliximab (Remicade), the first biologic therapy approved for the treatment of inflammatory bowel diseases (IBD), did not result in lower rates of hospitalizations or intestinal surgeries among patients living with IBD in Ontario, according to a study published by authors from several Canadian hospitals and ICES in the journal Gut.

Read More: Comparator Therapy News and Comparator Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.